Gilead Sciences Inc. said Norbert Bischofberger is stepping down as the company's chief scientific officer and executive vice president of research and development, effective at the end of April.
Bischofberger joined the biopharmaceutical company in 1990, has held the executive vice president role since 2000 and became the chief scientific officer in 2007. He will stay with Gilead Sciences until July.
John McHutchison will replace Bischofberger as chief scientific officer. McHutchison will be responsible for the company's R&D organization. He is serving as Gilead's executive vice president of clinical research.
The company has also appointed Andrew Cheng as chief medical officer, effective in April. Cheng is Gilead's executive vice president of clinical R&D operations.
